LEHI, Utah, Oct. 23, 2025 — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies targeting the root causes of inflammation-driven diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, ofirnoflast (HT-6184), for the treatment of Myelodysplastic Syndromes (MDS). MDS represents a group of rare bone marrow disorders characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia (AML).
Science Significance
Ofirnoflast is a first-in-class NEK7 allosteric modulator designed to regulate the NLRP3 inflammasome, a key driver of chronic inflammation. In MDS, excessive inflammasome activation contributes to ineffective hematopoiesis, leading to anemia, infection susceptibility, and bleeding complications. Traditional therapies, such as hypomethylating agents and growth factors, often fail to address these upstream inflammatory mechanisms. By selectively modulating NEK7, ofirnoflast aims to restore immune homeostasis and improve blood-cell production without inducing broad immunosuppression. Alan F. List, MD, former CEO of Moffitt Cancer Center and member of Halia’s Scientific Advisory Board, emphasized that the therapy’s approach is distinctive: “Ofirnoflast targets the underlying inflammatory drivers of MDS rather than merely managing downstream symptoms, potentially redefining treatment paradigms for inflammation-linked bone marrow failure.”
Regulatory Significance
The FDA grants ODD to therapies intended for rare diseases affecting fewer than 200,000 patients in the U.S. at the time of designation. Orphan-drug status provides a suite of regulatory incentives, including tax credits for qualified clinical testing, exemption from FDA user fees, and seven years of market exclusivity upon approval. The designation may also enable Halia Therapeutics to access FDA grant programs supporting clinical research in rare diseases, accelerating the path to potential approval. “This designation validates the scientific rationale behind our approach and strengthens our commitment to advancing treatment options for MDS patients,” said David Bearss, PhD, Chief Executive Officer of Halia Therapeutics. “It also underscores the FDA’s recognition of inflammasome-targeted therapies as an emerging frontier in hematology.”
Business Significance
Advertisement
Ofirnoflast is Halia’s lead compound, representing a strategically important asset in the company’s pipeline of inflammation-resolving therapies. Beyond MDS, the therapy is being investigated in multiple disease areas, including obesity (in combination with semaglutide to address adipose inflammation and metabolic dysregulation) and Alzheimer’s disease in genetically at-risk populations. The Orphan Drug Designation positions Halia for enhanced commercial and investment opportunities. Orphan status not only confers potential market exclusivity but also increases the attractiveness of the asset for strategic partnerships, licensing agreements, and potential future M&A activity. Analysts note that successful development could significantly expand Halia’s footprint in the high-value rare disease and hematology sectors.
Patients’ Significance
MDS primarily affects older adults and currently available therapies provide limited efficacy and do not directly address the disease’s inflammatory roots. Patients often face anemia, recurrent infections, and bleeding, significantly impacting quality of life. By targeting NEK7 and modulating inflammasome activity, ofirnoflast holds the promise of a disease-modifying therapy capable of improving hematologic outcomes and restoring bone marrow function. “Patients with MDS urgently need innovative therapies that address the underlying mechanisms of their disease,” said Dr. List. “Ofirnoflast represents a potential breakthrough by focusing on inflammasome-driven pathology rather than only mitigating secondary symptoms.”
Policy Significance
Orphan Drug Designation also carries broader policy implications. By incentivizing the development of therapies for rare diseases, the FDA encourages innovation in areas that are often underserved by conventional drug development models. Halia’s approach exemplifies this policy objective by leveraging cutting-edge insights into inflammasome biology to tackle complex, chronic conditions that have historically lacked effective therapies. Additionally, the designation aligns with national priorities to expand therapeutic options for rare hematologic disorders and support translational research bridging basic science discoveries with clinical applications. The company may also leverage public-private partnerships and grant programs to accelerate development and broaden patient access.
Transaction Highlights
The FDA’s Orphan Drug Designation for ofirnoflast (HT-6184) represents a key milestone for Halia Therapeutics, enhancing the company’s regulatory, clinical, and commercial positioning in rare hematologic disorders. The designation provides incentives such as seven years of potential U.S. market exclusivity, tax credits for qualified clinical testing, and exemption from FDA user fees, strengthening the financial and strategic attractiveness of the asset. From a business perspective, the designation increases opportunities for strategic partnerships, licensing agreements, and potential M&A activity, as investors and collaborators gain confidence in the therapy’s market potential and differentiated mechanism of action. Clinically, the recognition supports the advancement of ongoing Phase 2 studies in MDS and informs parallel programs in obesity and Alzheimer’s disease, demonstrating the versatility of the NEK7–NLRP3 inflammasome targeting approach. Overall, the transaction highlights the company’s ability to leverage regulatory incentives, advance innovative therapies, and position itself as a leader in inflammation-driven and rare disease therapeutics, laying the foundation for future clinical, commercial, and investor engagement.
Source: Halia Therapeutics Press Release
